RxSight (RXST) Competitors $9.28 +0.55 (+6.30%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$9.24 -0.04 (-0.43%) As of 08/22/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXST vs. BLFS, MDXG, ESTA, PLSE, INMD, IRMD, TNDM, KMTS, EMBC, and SIBNShould you be buying RxSight stock or one of its competitors? The main competitors of RxSight include BioLife Solutions (BLFS), MiMedx Group (MDXG), Establishment Labs (ESTA), Pulse Biosciences (PLSE), InMode (INMD), iRadimed (IRMD), Tandem Diabetes Care (TNDM), Kestra Medical Technologies (KMTS), Embecta (EMBC), and SiBone (SIBN). These companies are all part of the "medical equipment" industry. RxSight vs. Its Competitors BioLife Solutions MiMedx Group Establishment Labs Pulse Biosciences InMode iRadimed Tandem Diabetes Care Kestra Medical Technologies Embecta SiBone BioLife Solutions (NASDAQ:BLFS) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings. Does the media prefer BLFS or RXST? In the previous week, RxSight had 34 more articles in the media than BioLife Solutions. MarketBeat recorded 40 mentions for RxSight and 6 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.39 beat RxSight's score of 0.03 indicating that BioLife Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 2 Very Positive mention(s) 2 Positive mention(s) 30 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of BLFS or RXST? 93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by insiders. Comparatively, 9.6% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate BLFS or RXST? BioLife Solutions currently has a consensus price target of $31.29, indicating a potential upside of 20.75%. RxSight has a consensus price target of $10.00, indicating a potential upside of 7.76%. Given BioLife Solutions' stronger consensus rating and higher possible upside, research analysts plainly believe BioLife Solutions is more favorable than RxSight.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLife Solutions 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13RxSight 2 Sell rating(s) 8 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.91 Is BLFS or RXST more profitable? BioLife Solutions has a net margin of -5.39% compared to RxSight's net margin of -21.93%. BioLife Solutions' return on equity of 0.16% beat RxSight's return on equity.Company Net Margins Return on Equity Return on Assets BioLife Solutions-5.39% 0.16% 0.14% RxSight -21.93%-11.56%-10.31% Which has more volatility & risk, BLFS or RXST? BioLife Solutions has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, RxSight has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Which has better earnings and valuation, BLFS or RXST? BioLife Solutions has higher earnings, but lower revenue than RxSight. BioLife Solutions is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLife Solutions$82.25M15.09-$20.18M-$0.12-215.92RxSight$139.93M2.71-$27.45M-$0.80-11.60 SummaryBioLife Solutions beats RxSight on 13 of the 17 factors compared between the two stocks. Get RxSight News Delivered to You Automatically Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXST vs. The Competition Export to ExcelMetricRxSightMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$357.20M$6.88B$5.76B$9.58BDividend YieldN/A1.31%4.41%4.10%P/E Ratio-11.6027.4531.1026.04Price / Sales2.7175.51433.45102.77Price / CashN/A21.3437.7358.48Price / Book1.376.889.536.61Net Income-$27.45M$176.42M$3.26B$265.56M7 Day Performance10.08%1.45%2.10%1.97%1 Month Performance17.47%-2.71%2.81%-0.36%1 Year Performance-83.56%9.40%30.56%19.03% RxSight Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXSTRxSight1.0116 of 5 stars$9.28+6.3%$10.00+7.8%-82.9%$357.20M$139.93M-11.60220Trending NewsShort Interest ↑BLFSBioLife Solutions2.5497 of 5 stars$22.37-1.4%$31.29+39.9%+6.0%$1.09B$82.25M-186.40440News CoveragePositive NewsInsider TradeHigh Trading VolumeMDXGMiMedx Group3.2618 of 5 stars$7.04+0.3%$12.00+70.5%+11.1%$1.04B$348.88M33.53870Positive NewsESTAEstablishment Labs1.9306 of 5 stars$33.63-3.4%$55.80+65.9%+0.7%$1.01B$166.02M-11.031,018News CoverageAnalyst ForecastHigh Trading VolumePLSEPulse Biosciences3.5093 of 5 stars$14.88+1.2%$22.00+47.8%-20.8%$989.60M$700K0.00140INMDInMode1.9906 of 5 stars$13.80-2.2%$18.04+30.7%-4.4%$891.88M$394.82M5.59480Positive NewsIRMDiRadimed4.6421 of 5 stars$70.00+0.1%$72.00+2.9%+62.5%$889.51M$73.24M43.21110Positive NewsTNDMTandem Diabetes Care4.6054 of 5 stars$10.11-10.0%$22.67+124.2%-71.9%$758.80M$940.20M-3.272,650Analyst ForecastKMTSKestra Medical TechnologiesN/A$14.65+0.9%$27.33+86.6%N/A$745.58M$59.81M0.00300EMBCEmbecta4.8382 of 5 stars$12.73+3.7%$19.00+49.3%+9.0%$717.67M$1.12B8.902,100Positive NewsHigh Trading VolumeSIBNSiBone4.1755 of 5 stars$15.40-1.8%$23.67+53.7%+10.0%$676.45M$167.18M-27.50350News CoverageInsider Trade Related Companies and Tools Related Companies BioLife Solutions Alternatives MiMedx Group Alternatives Establishment Labs Alternatives Pulse Biosciences Alternatives InMode Alternatives iRadimed Alternatives Tandem Diabetes Care Alternatives Kestra Medical Technologies Alternatives Embecta Alternatives SiBone Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXST) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access